Title: 2016 ACVIM Forum Research Abstract Program Document date: 2016_5_31
ID: 2y1y8jpx_206
Snippet: Methods: With PACUC approval, eligible dogs were enrolled in a 3 + 3 dose escalating cohort study of Folate-Tubulysin (Endocyte, West Lafayette, IN). Inclusion criteria were histologic diagnosis of TCC, presence of FRs on the TCC cells detected by immunohistochemistry and/or folate uptake in the TCC detected by nuclear scintigraphy, and informed pet owner consent. The initial dose was 0.2 mg/kg given intravenously every two weeks, with intra-and .....
Document: Methods: With PACUC approval, eligible dogs were enrolled in a 3 + 3 dose escalating cohort study of Folate-Tubulysin (Endocyte, West Lafayette, IN). Inclusion criteria were histologic diagnosis of TCC, presence of FRs on the TCC cells detected by immunohistochemistry and/or folate uptake in the TCC detected by nuclear scintigraphy, and informed pet owner consent. The initial dose was 0.2 mg/kg given intravenously every two weeks, with intra-and inter-cohort escalation by 0.02 mg/kg after at least two consecutive treatments. Escalation continued until dose limiting toxicity (DLT) was observed and the maximum tolerated dose (MTD) determined.
Search related documents:
Co phrase search for related documents- cohort study and histologic diagnosis: 1
- cohort study and immunohistochemistry detect: 1
- cohort study and inclusion criterion: 1
- cohort study and initial dose: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date